Neuraxis (NRXS) Shares Outstanding (2022 - 2026)
Neuraxis (NRXS) posted Shares Outstanding (Entity) of $11.5 million for Q1 2026, up 7.48% sequentially from $10.7 million in Q4 2025, and up 58.68% YoY from $7.2 million in Q1 2025.
Neuraxis (NRXS) Shares Outstanding (2022 - 2026) Analysis & Trends
Neuraxis has reported Shares Outstanding (Entity) for 5 years, with the latest figure at $11.5 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 58.68% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (up 58.68% YoY) and the FY2025 annual result came in at $10.7 million, up 52.4% from the prior year.
- Shares Outstanding (Entity) advanced to $11.5 million in Q1 2026 per NRXS's latest filing, from $10.7 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $11.5 million in Q1 2026 and troughed at $1.9 million in Q2 2022.
- A 5-year average of $5.8 million and a median of $6.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) climbed 1.09% in 2023, then soared 248.47% in 2024.
- Over 5 years, Shares Outstanding (Entity) stood at $2.0 million in 2022, then soared by 65.65% to $3.3 million in 2023, then jumped by 114.93% to $7.0 million in 2024, then jumped by 52.4% to $10.7 million in 2025, then grew by 7.48% to $11.5 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $11.5 million, $10.7 million, and $9.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | 12.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.12 Mn |
| Mar 31, 2026 | 10.95 Mn |
| Dec 31, 2025 | 9.08 Mn |
| Sep 30, 2025 | 9.88 Mn |
| Jun 30, 2025 | 8.52 Mn |
| Mar 31, 2025 | 7.46 Mn |
| Dec 31, 2024 | 6.92 Mn |
| Sep 30, 2024 | 7.17 Mn |
| Jun 30, 2024 | 6.92 Mn |
| Mar 31, 2024 | 6.55 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Sep 30, 2023 | 3.63 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | 2.00 Mn |
| Sep 30, 2022 | 1.99 Mn |
| Jun 30, 2022 | 1.97 Mn |